Recombinant Erythropoietin to Improve Athletic Performance
- 7 March 1991
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 324 (10) , 698-699
- https://doi.org/10.1056/nejm199103073241014
Abstract
Since the beginning of competitive athletics, people have sought methods to enhance their performance. "Blood doping," the use of red-cell transfusions to increase the oxygen-carrying capacity of the blood, has been used by some athletes to enhance performance in endurance events such as cycling and long-distance running. In 1985, Klein discussed the medical and ethical issues surrounding blood doping.1 He pointed out that while it is possible for athletes to donate blood for their own eventual use — or to have friends or relatives donate blood — it is not without danger. The processes of donation, storage, and reinfusion very likely would be carried out under suboptimal or even medically unacceptable conditions, and the use of homologous blood would expose the athlete to the risk of transfusion-transmitted disease.Keywords
This publication has 7 references indexed in Scilit:
- Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal DiseaseAnnals of Internal Medicine, 1989
- The effects of red blood cell infusion on 10-km race timeJAMA, 1987
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987
- Characterization and Biological Effects of Recombinant Human ErythropoietinImmunobiology, 1986
- Blood Transfusion and AthleticsNew England Journal of Medicine, 1985
- Effect of induced erythrocythemia on aerobic work capacityJournal of Applied Physiology, 1980
- Response to exercise after blood loss and reinfusion.Journal of Applied Physiology, 1972